PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study.

Abstract Although current guidelines recommend β-blocker after acute myocardial infarction (MI), the role of β-blocker has not been well investigated in the modern reperfusion era. In particular, the benefit of vasodilating β-blocker over conventional β-blocker is still unexplored.
PMID
Related Publications

Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention.

Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.

β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.

Authors

Mayor MeshTerms
Keywords

acute myocardial infarction

beta‐blocker

cohort study

prognosis

propensity score

Journal Title journal of the american heart association
Publication Year Start




PMID- 29066446
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 6
IP  - 10
DP  - 2017 Oct 24
TI  - Benefit of Vasodilating beta-Blockers in Patients With Acute Myocardial
      Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter
      Cohort Study.
LID - e007063 [pii]
LID - 10.1161/JAHA.117.007063 [doi]
AB  - BACKGROUND: Although current guidelines recommend beta-blocker after acute
      myocardial infarction (MI), the role of beta-blocker has not been well
      investigated in the modern reperfusion era. In particular, the benefit of
      vasodilating beta-blocker over conventional beta-blocker is still unexplored.
      METHODS AND RESULTS: Using nation-wide multicenter Korean Acute Myocardial
      Infarction Registry data, we analyzed clinical outcomes of 7127 patients with
      acute MI who underwent successful percutaneous coronary intervention with stents 
      and took beta-blockers: vasodilating beta-blocker (n=3482), and conventional
      beta-blocker (n=3645). In the whole population, incidence of cardiac death at 1
      year was significantly lower in the vasodilating beta-blocker group (vasodilating
      beta-blockers versus conventional beta-blockers, 1.0% versus 1.9%; P=0.003). In
      2882 pairs of propensity score-matched population, the incidence of cardiac death
      was significantly lower in the vasodilating beta-blocker group (1.1% versus 1.8%;
      P=0.028). Although incidences of MI (1.1% versus 1.5%; P=0.277), any
      revascularization (2.8% versus 3.0%; P=0.791), and hospitalization for heart
      failure (1.4% versus 1.9%; P=0.210) were not different between the 2 groups,
      incidences of cardiac death or MI (2.0% versus 3.1%; P=0.010), cardiac death, MI,
      or hospitalization for heart failure (3.0% versus 4.5%; P=0.003), cardiac death, 
      MI, or any revascularization (3.9% versus 5.3%; P=0.026), and cardiac death, MI, 
      any revascularization, or hospitalization for heart failure (4.8% versus 6.5%;
      P=0.011) were significantly lower in the vasodilating beta-blocker group.
      CONCLUSIONS: Vasodilating beta-blocker therapy resulted in better clinical
      outcomes than conventional beta-blocker therapy did in patients with acute MI in 
      the modern reperfusion era. Vasodilating beta-blockers could be recommended
      preferentially to conventional ones for acute MI patients.
CI  - (c) 2017 The Authors. Published on behalf of the American Heart Association,
      Inc., by Wiley.
FAU - Chung, Jaehoon
AU  - Chung J
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Han, Jung-Kyu
AU  - Han JK
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Kim, Young Jo
AU  - Kim YJ
AD  - Department of Internal Medicine, Yeungnam University Hospital, Daegu, Korea.
FAU - Kim, Chong Jin
AU  - Kim CJ
AD  - Department of Internal Medicine, Kyunghee University Hospital, Seoul, Korea.
FAU - Ahn, Youngkeun
AU  - Ahn Y
AD  - Department of Internal Medicine, Chonnam National University Hospital, Kwangju,
      Korea.
FAU - Chan Cho, Myeong
AU  - Chan Cho M
AD  - Department of Internal Medicine, Chungbuk National University Hospital, Cheongju,
      Korea.
FAU - Chae, Shung Chull
AU  - Chae SC
AD  - Department of Internal Medicine, Kyungpook National University Hosptial, Daegu,
      Korea.
FAU - Chae, In-Ho
AU  - Chae IH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Sungnam, Korea.
FAU - Chae, Jei Keon
AU  - Chae JK
AD  - Department of Cardiovascular Medicine, Medical School of Chonbuk National
      University, Jeonju, Korea.
FAU - Seong, In-Whan
AU  - Seong IW
AD  - Department of Cardiology in Internal Medicine, Chungnam National University
      Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
FAU - Yang, Han-Mo
AU  - Yang HM
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Park, Kyung-Woo
AU  - Park KW
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Kang, Hyun-Jae
AU  - Kang HJ
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Koo, Bon-Kwon
AU  - Koo BK
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea.
FAU - Jeong, Myung Ho
AU  - Jeong MH
AD  - Department of Internal Medicine, Chonnam National University Hospital, Kwangju,
      Korea.
FAU - Kim, Hyo-Soo
AU  - Kim HS
AD  - Cardiovascular Center, Department of Internal Medicine, Seoul National University
      Hospital, Seoul, Korea [email protected]
CN  - investigators for Korea Acute Myocardial Infarction Registry (KAMIR)
LA  - eng
PT  - Journal Article
DEP - 20171024
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
PMC - PMC5721887
OTO - NOTNLM
OT  - acute myocardial infarction
OT  - beta-blocker
OT  - cohort study
OT  - prognosis
OT  - propensity score
IR  - Ahn TH
FIR - Ahn, Tae Hoon
IR  - Cha KS
FIR - Cha, Kwang Soo
IR  - Gwon HC
FIR - Gwon, Hyeon-Cheol
IR  - Hwang JY
FIR - Hwang, Jin-Yong
IR  - Joo SJ
FIR - Joo, Seung Jae
IR  - Kim DI
FIR - Kim, Doo-Il
IR  - Kim KB
FIR - Kim, Kwon-Bae
IR  - Oh DJ
FIR - Oh, Dong Joo
IR  - Oh SK
FIR - Oh, Seok Kyu
IR  - Seung KB
FIR - Seung, Ki-Bae
IR  - Yoon JH
FIR - Yoon, Jung-Han
EDAT- 2017/10/27 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/10/26 06:00
PHST- 2017/10/26 06:00 [entrez]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - JAHA.117.007063 [pii]
AID - 10.1161/JAHA.117.007063 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2017 Oct 24;6(10). pii: JAHA.117.007063. doi:
      10.1161/JAHA.117.007063.